skip to Main Content

2016, 01, 18 — Change in the Board of Directors and Scientific Advisory Board of PILA PHARMA

18 January 2016

The Chairman of Pila Pharma Board of Director, Mogens Vang Rasmussen has decided to resign from his position in PILA PHARMA at the end of 2015 due to an increased workload as co-owner and partner of Vesicon, a newly established company with the ambition to bring new and innovative ultra sound devices to the market.

PILA PHARMA established a Board of Directors in January 2015 with highly skilled pharmaceutical professionals, and Mogens Vang Rasmussen accepted to head up the Board of Directors. He brought a long time experience from the life science industry including the understanding of the diabetes market in addition to insight into strategy, planning and financing.

Mogens Vang Rasmussen has made a tremendous contribution in the start-up period of PILA PHARMA in defining a solid direction for the company’s strategy and development plans, says CEO Dorte X. Gram. I’m grateful that Mogens, with his significant background in biotech and the pharmaceutical industry,
accepted the chairmanship in this initial phase.

PILA PHARMA is now moving to another phase after the start-up period and needs to consolidate further into a small company.
New Chairman of the Board, Jan R. Nilsson, will help in this transition and brings to PILA PHARMA substantial business managerial experience from various positions, e.g. as CEO for Securitas-Direct / Verisure in Norway, Belgium, Holland and Denmark.

We are very proud to have been able to attract Jan R. Nilsson to the Board of Directors of PILA PHARMA, says CEO Dorte X. Gram, and I personally look much forward to working together with Jan in consolidating and further developing the company both on the administrative side as well as on the operational side.

Further, to strengthen the Scientific Advisory Board in terms of Intellectual Property Rights of our future business, we are pleased to welcome Jens Viktor Nørgaard who is a European Patent Attorney and a leading expert in Biotech and Pharma patenting.

Jens Viktor Nørgaard has already played a significant role in PILA PHARMAs history in working with me on the patenting process that eventually led to the issue of the use-patents, says CEO Dorte X. Gram. I am very pleased, that Jens Viktor Nørgaard has accepted to join our Scientific Advisory Board, and I trust that he will ensure that PILA PHARMA will have the right focus on Intellectual Property Rights going forward.

2015, 09, 11 — Change in the PILA PHARMA Board of Directors


Director of the Board, Axel Nemetz, will resign from his position

In January 2015, PILA PHARMA established a Board of Directors, which encompassed highly skilled pharmaceutical professionals. At that time, Axel Nemetz was invited to join the Board of Directors due to his thorough understanding of the diabetes market, including insight into strategy, planning and financing.

“Axel Nemetz has contributed significantly in transforming PILA PHARMA into a professional business unit and we want to thank him a lot for his valuable input to PILA PHARMA’s strategic discussions. We wish him the best of luck in his new endeavours and his role as Head of Market Entry Strategies, Life Sciences & Healthcare at IBM”, says CEO Dorte X. Gram.

PILA PHARMA is moving towards a new investment round and in association with that, a new Director of the Board will be announced.

2015, 02, 18 — New method gives hope of treatment of diabetes


Press release 2015-02-18

Download as PDF

New method gives hope of treatment of diabetes

More and more adults’ get type 2 diabetes. Today, more than 8% of the earths grown-up population have the disease and the negative development increases by 7,5% per year. Today treatment is mainly focused on delaying the time to treatment of the life long disease with insulin. PILA PHARMA, which has been established at Medeon Science Park in Malmø, is dedicated to develop a novel approach of the treatment of type 2 diabetes, and is currently in the process of starting a project, which already has showed promising pre-clinical results. Almi Invest has made an investment in PILA PHARMA.

– PILA PHARMA has concluded pre-clinical trials and demonstrated some very positive and exiting results. For obvious reasons investments in the development of pharmaceutical products is extremely high risk. However, this is exactly the mission for Almi Invest to invest in high-risk projects, and this project needs a decent chance to be seriously examined. So even if it will be a long journey to a safe and efficient pharmaceutical product or treatment method, the need is immense and the market is huge says Per Antonsson, Investment Manager at Almi Invest.

New class of an oral pharmaceutical product for the treatment of type 2 diabetes

The objective of the project is to develop a new class of an oral pharmaceutical product to treat newly diagnosed type 2 diabetic patients in combination with other glucose regulating pharmaceutical products hereby delaying the treatment with insulin to delay and possible avoid the late complications and debilitating diseases associated with diabetes.

The woman behind the Company

Dorte Xenia Gram is the owner of PILA PHARMA.

– The investment from Almi Invest confirms that they believe in our concept, which is extremely important for us. The investment from Almi Invest enable us to continue our development and ultimately investigate how a smaller number of patients will react in an acute glucose tolerance study says Dorte Xenia Gram, CEO at PILA PHARMA.

Dorte X. Gram has an extensive network of experts and diabetes competences linked to her company and bring herself diabetes expertise from her previous position within diabetes at the Danish diabetes company Novo Nordisk. When Novo Nordisk, for strategic reasons, decided to focus their research and development on proteins, Dorte X. Gram had the chance to acquire the use patent for the active ingredient, which is the cornerstone of the development to an active oral pharmaceutical product for the treatment of newly diagnosed type 2 diabetic patients.

Professionalism in the Board of Directors

In association with Almi Invest’s investment, the Board of Directors has been expanded with individuals with a broad-based experience from public life science companies. In addition to Per Antonsson, which represents Almi Invest, Axel Nemetz and Mogens Vang Rasmussen have been added to the company’s Board of Directors. Axel has a background as Global Head of m-health at Vodafone and before that he was European Head of Strategy at Novo Nordisk. Mogens has a background as Finance Director, Planning and Investor Relations, Novo Nordisk of North America, New York, USA and later he served as CEO and CFO/COO at Zealand Pharma, a biotech company with diabetes products.

For further information please contact:

  • Maria Kessling, Head of Communication Almi Invest; +4676-880 88 10, maria@kessling @
  • Per Antonsson, Investment Manager Almi Invest; +4670-872 87 17,
  • Dorte Xenia Gram, CEO, PILA PHARMA +46 (0) 73 903 6969;

About Almi Invest:

Almi Invest invests in Swedish companies with scalable business concepts and prospects for long-term capital growth. Through the support of our experienced investment managers, capital and networks, we create opportunities for businesses to grow and compete in a global market. We invest from the seed phase to the expansion phase. We are located across the whole of Sweden, with regional knowledge and an international perspective. Our portfolio consists of 400 growth companies in many different industries. Almi Invest is a subsidiary of the Almi Group.
Back To Top